Monopar Therapeutics Inc. MNPR | NASDAQ
|2026-08-21
Company Overview:
6.9 Year MNPR Performance Metrics:
Build Custom Charts
MNPR Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for MNPR
Based on past 6.9-year performance, here are MNPR growth metrics:
Share price CAGR of -8.46%
Dividend CAGR of +0%
Using MNPR CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| MNPR (DRIP) | MNPR - No DRIP | |
|---|---|---|
| Current Price | $72.00 | $72.00 |
| Start Shares | 138.89 | 138.89 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 138.89 | 138.89 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $29.75 | $72.00 |
| Total Dividends | $0 | $0 |
| Final Value | $4,132 | $10,000 |
NOTE: Above numbers are our estimate based on MNPR's Dividend and Price CAGR over past 6.9 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Monopar Therapeutics Inc. (MNPR) had its IPO on 2019-12-19, and is traded on NASDAQ stock exchange.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
MNPR website: https://www.monopartx.com
DCF Model — MNPR
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
